omeprazole and dorzolamide

omeprazole has been researched along with dorzolamide in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Hussar, DA1
Cantor, LB1

Reviews

1 review(s) available for omeprazole and dorzolamide

ArticleYear
An update on bimatoprost in glaucoma therapy.
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amides; Antihypertensive Agents; Benzimidazoles; Bimatoprost; Clinical Trials as Topic; Cloprostenol; Drug Combinations; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Lipids; Omeprazole; Ophthalmic Solutions; Prostaglandins F, Synthetic; Sulfonamides; Thiophenes

2002

Other Studies

3 other study(ies) available for omeprazole and dorzolamide

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
New therapeutic agents marketed in 1995.
    Pennsylvania medicine, 1996, Volume: 99, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration

1996